BSE Live
Apr 15, 16:00Prev. Close
10753.65
Open Price
10500.00
Bid Price (Qty.)
10530.00 (3)
Offer Price (Qty.)
10753.65 (48)
NSE Live
Apr 15, 15:59Prev. Close
10732.60
Open Price
10310.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
10732.60 (91)
| Key Financial Ratios of GlaxoSmithKline Consumer Healthcare (in Rs. Cr.) | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 233.69 | 166.47 | 156.15 | 163.34 | 138.77 | |
| Diluted EPS (Rs.) | 233.69 | 166.47 | 156.15 | 163.34 | 138.77 | |
| Cash EPS (Rs.) | 248.08 | 181.78 | 171.41 | 176.99 | 153.53 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 973.65 | 828.70 | 742.51 | 581.53 | 502.44 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 973.65 | 828.70 | 742.51 | 581.53 | 502.44 | |
| Dividend / Share(Rs.) | 105.00 | 75.00 | 70.00 | 70.00 | 55.00 | |
| Revenue from Operations/Share (Rs.) | 1,137.07 | 1,026.39 | 949.05 | 1,024.53 | 1,024.26 | |
| PBDIT/Share (Rs.) | 374.17 | 271.25 | 256.18 | 264.80 | 226.36 | |
| PBIT/Share (Rs.) | 359.78 | 255.95 | 240.92 | 251.14 | 211.60 | |
| PBT/Share (Rs.) | 359.59 | 255.46 | 240.26 | 250.95 | 211.42 | |
| Net Profit/Share (Rs.) | 233.69 | 166.47 | 156.15 | 163.34 | 138.77 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 32.90 | 26.42 | 26.99 | 25.84 | 22.09 | |
| PBIT Margin (%) | 31.64 | 24.93 | 25.38 | 24.51 | 20.65 | |
| PBT Margin (%) | 31.62 | 24.88 | 25.31 | 24.49 | 20.64 | |
| Net Profit Margin (%) | 20.55 | 16.21 | 16.45 | 15.94 | 13.54 | |
| Return on Networth / Equity (%) | 24.00 | 20.08 | 21.02 | 28.08 | 27.61 | |
| Return on Capital Employed (%) | 35.56 | 19.07 | 19.54 | 25.59 | 25.04 | |
| Return on Assets (%) | 16.19 | 12.93 | 13.25 | 15.26 | 14.51 | |
| Total Debt/Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Asset Turnover Ratio (%) | 78.80 | 79.74 | 80.55 | 95.77 | 107.16 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 2.90 | 2.62 | 2.59 | 2.07 | 1.96 | |
| Quick Ratio (X) | 2.65 | 2.38 | 2.31 | 1.81 | 1.68 | |
| Inventory Turnover Ratio (X) | 10.27 | 10.54 | 8.66 | 9.33 | 9.24 | |
| Dividend Payout Ratio (NP) (%) | 32.09 | 42.04 | 44.83 | 42.85 | 39.63 | |
| Dividend Payout Ratio (CP) (%) | 30.23 | 38.50 | 40.83 | 39.54 | 35.82 | |
| Earnings Retention Ratio (%) | 67.91 | 57.96 | 55.17 | 57.15 | 60.37 | |
| Cash Earnings Retention Ratio (%) | 69.77 | 61.50 | 59.17 | 60.46 | 64.18 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 26,235.61 | 22,048.05 | 18,612.42 | 22,668.86 | 24,196.97 | |
| EV/Net Operating Revenue (X) | 5.49 | 5.11 | 4.66 | 5.26 | 5.62 | |
| EV/EBITDA (X) | 16.67 | 19.33 | 17.28 | 20.36 | 25.42 | |
| MarketCap/Net Operating Revenue (X) | 6.34 | 5.94 | 5.44 | 5.89 | 6.15 | |
| Retention Ratios (%) | 67.90 | 57.95 | 55.16 | 57.14 | 60.36 | |
| Price/BV (X) | 7.41 | 7.36 | 6.95 | 10.38 | 12.54 | |
| Price/Net Operating Revenue | 6.34 | 5.94 | 5.44 | 5.89 | 6.15 | |
| Earnings Yield | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 |
01.02.2022
Storyboard18 | Paracetamol brand wars: Is Dolo rival Crocin feeling the chills?
27.02.2020
Chandigarh NCLT nod for HUL, GlaxoSmithKline Consumer Healthcare merger deal
07.02.2020
GlaxoSmith Con Standalone December 2019 Net Sales at Rs 1,158.86 crore, up 3.76% Y-o-Y
07.08.2019
Hold GlaxoSmithKline Consumer Healthcare target of Rs 7931: Sharekhan
07.02.2020
GlaxoSmith Con Standalone December 2019 Net Sales at Rs 1,158.86 crore, up 3.76% Y-o-Y
06.02.2020
02.08.2019
GlaxoSmith Con Standalone June 2019 Net Sales at Rs 1,194.32 crore, up 7.87% Y-o-Y
01.08.2019
10.07.2019
GSK Consumer Q1 PAT seen up 15.6% YoY to Rs. 231.8 cr: ICICI Direct
15.04.2019
GSK Consumer Q4 PAT seen up 10.1% YoY to Rs. 233.1 cr: ICICI Direct
08.04.2019
GSK Consumer Q4 PAT seen up 15.7% YoY to Rs. 245.1 cr: Kotak
16.01.2019
GlaxoSmithKline Consumer Healthcare Q3 PAT seen up 17.1% YoY to Rs. 191.6 cr: Prabhudas Lilladher
13.05.2024
Varun Beverages Q1 results: Net Profit rises 25% to Rs 548 crore
06.05.2024
Britannia forecasts 'manageable' inflation amid concern over wheat, sugar prices
03.05.2024
Britannia Q4: Net profit falls 3.8% to Rs 537 crore, revenue up marginally
06.02.2024
Britannia Q3 results: Consolidated PAT plunges 40% to Rs 556 crore but marginally misses estimates
02.05.2024
Britannia Q4 results preview: PAT may decline 3% as rural demand fails to see substantial recovery
24.04.2024
Nestle India Q1 preview: Strong revenue, profit growth expected on price hikes
05.02.2024
Britannia Q3 preview: Net profit to rise 2%, volumes to grow in low single-digit
31.10.2023
Britannia Industries Q2: Net profit may rise 11% on-year on flat revenue; volume growth in focus
26.04.2024
Nestle India Q4 review: Brokerages mixed despite earnings beat, inflation to pressure margins
30.10.2023
28.07.2023
Nestle gains on double-digit growth in all categories in Q1, brokerage views mixed
20.10.2021
Nestle India’s September quarter just about satiating. Higher input costs pose risk